ATAI vs. NKTX, PGEN, TERN, URGN, RANI, HRTX, NLTX, SBTX, AVIR, and ORGO
Should you be buying Atai Life Sciences stock or one of its competitors? The main competitors of Atai Life Sciences include Nkarta (NKTX), Precigen (PGEN), Terns Pharmaceuticals (TERN), UroGen Pharma (URGN), Rani Therapeutics (RANI), Heron Therapeutics (HRTX), Neoleukin Therapeutics (NLTX), Silverback Therapeutics (SBTX), Atea Pharmaceuticals (AVIR), and Organogenesis (ORGO). These companies are all part of the "pharmaceutical preparations" industry.
Atai Life Sciences (NASDAQ:ATAI) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, community ranking, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.
Atai Life Sciences presently has a consensus price target of $10.50, suggesting a potential upside of 412.20%. Nkarta has a consensus price target of $17.83, suggesting a potential upside of 140.99%. Given Atai Life Sciences' higher probable upside, research analysts plainly believe Atai Life Sciences is more favorable than Nkarta.
Atai Life Sciences received 280 more outperform votes than Nkarta when rated by MarketBeat users. However, 71.43% of users gave Nkarta an outperform vote while only 65.92% of users gave Atai Life Sciences an outperform vote.
Atai Life Sciences has higher revenue and earnings than Nkarta. Atai Life Sciences is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.
In the previous week, Atai Life Sciences had 3 more articles in the media than Nkarta. MarketBeat recorded 3 mentions for Atai Life Sciences and 0 mentions for Nkarta. Nkarta's average media sentiment score of 0.00 beat Atai Life Sciences' score of -0.09 indicating that Nkarta is being referred to more favorably in the news media.
28.4% of Atai Life Sciences shares are held by institutional investors. Comparatively, 80.5% of Nkarta shares are held by institutional investors. 30.0% of Atai Life Sciences shares are held by insiders. Comparatively, 5.6% of Nkarta shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Atai Life Sciences has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. Comparatively, Nkarta has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500.
Nkarta has a net margin of 0.00% compared to Atai Life Sciences' net margin of -12,810.51%. Nkarta's return on equity of -38.06% beat Atai Life Sciences' return on equity.
Summary
Atai Life Sciences and Nkarta tied by winning 8 of the 16 factors compared between the two stocks.
Get Atai Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATAI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Atai Life Sciences Competitors List
Related Companies and Tools
